DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
First-in-Class CBP/p300 Inhibitor TT125-802 Shows Promise in Treatment-Resistant NSCLC
TT125-802, a novel oral CBP/p300 bromodomain inhibitor, demonstrated early clinical activity in advanced solid tumors with a favorable safety profile in an ongoing phase 1 trial.
Dr. Elizabeth Mittendorf Outlines Vision as ASCO President-Elect to Advance Multidisciplinary Cancer Care and Workforce Support
Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.
Leon-nanodrugs Appoints Dr. Wolfgang Hofmann as CEO to Drive Nanoparticle Manufacturing Technology Commercialization
Munich-based leon-nanodrugs GmbH has appointed Dr. Wolfgang Hofmann as CEO to lead the company's transition from development to commercialization of its FR-JET® nanoparticle manufacturing technology.
AMPLITUDE Trial Shows Niraparib Combination Reduces Cancer Progression Risk by 37% in HRR-Mutant Metastatic Prostate Cancer
The phase III AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations.
Trastuzumab Deruxtecan Combination Reduces Disease Progression Risk by 44% in HER2-Positive Metastatic Breast Cancer
A new treatment combining trastuzumab deruxtecan (T-DXd) with pertuzumab reduced the risk of disease progression or death by 44% compared to standard care in HER2-positive metastatic breast cancer patients.
RLY-2608 Shows Promise in PIK3CA-Mutant Breast Cancer with Improved Tolerability Profile
RLY-2608, a mutant-selective PI3Kα inhibitor, combined with fulvestrant achieved a 38.7% overall response rate and 10.3-month median progression-free survival in patients with PIK3CA-mutant HR+/HER2- advanced breast cancer.
DLL3-Targeted CAR-T Therapy LB2102 Shows Promise in Relapsed/Refractory Small Cell Lung Cancer
LB2102, a DLL3-directed autologous CAR-T cell therapy, demonstrated preliminary antitumor activity with a 16.7% objective response rate and 66.7% disease control rate in patients with relapsed/refractory small cell lung cancer and large cell neuroendocrine carcinoma.
Anti-Inflammatory Diet Reduces Death Risk by 87% in Stage III Colon Cancer Patients
Patients with stage III colon cancer consuming the most pro-inflammatory diets had an 87% higher risk of death compared to those with the least inflammatory diets in a phase 3 clinical trial analysis.
Casdatifan Plus Cabozantinib Combination Shows 46% Response Rate in Kidney Cancer Trial
Arcus Biosciences reported a 46% confirmed overall response rate for the casdatifan plus cabozantinib combination in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.
Atezolizumab Plus Chemotherapy Reduces Recurrence Risk by 50% in Stage III dMMR Colon Cancer
The phase 3 ATOMIC trial demonstrated that adding atezolizumab to standard chemotherapy reduced the risk of recurrence or death by 50% in patients with stage III dMMR colon cancer.